Working… Menu

Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00662506
Recruitment Status : Completed
First Posted : April 21, 2008
Last Update Posted : September 21, 2017
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Brief Summary:
This phase I/II trial is studying the side effects and best dose of cediranib to see how well it works when given together with temozolomide and radiation therapy in treating patients with newly diagnosed glioblastoma. Cediranib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving cediranib together with temozolomide and radiation therapy may kill more tumor cells.

Condition or disease Intervention/treatment Phase
Adult Giant Cell Glioblastoma Adult Glioblastoma Adult Gliosarcoma Drug: Cediranib Maleate Procedure: Diffusion Tensor Imaging Procedure: Diffusion Weighted Imaging Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging Radiation: Fludeoxyglucose F-18 Radiation: Intensity-Modulated Radiation Therapy Other: Laboratory Biomarker Analysis Procedure: Perfusion Magnetic Resonance Imaging Procedure: Positron Emission Tomography Drug: Temozolomide Phase 1 Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 46 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ib/II Study of AZD2171 in Combination With Daily Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma Not Taking Enzyme-Inducing Anti-epileptic Drugs
Study Start Date : April 2008
Actual Primary Completion Date : April 2014
Actual Study Completion Date : April 2014

Arm Intervention/treatment
Experimental: Treatment (enzyme inhibitor therapy, chemotherapy, IMRT)
See Detailed Description
Drug: Cediranib Maleate
Given PO
Other Names:
  • AZD2171
  • AZD2171 Maleate
  • Recentin

Procedure: Diffusion Tensor Imaging
Undergo DTI
Other Name: DTI

Procedure: Diffusion Weighted Imaging
Undergo T1 weighted DCE-MRI
Other Names:
  • Diffusion Weighted MRI
  • Diffusion-Weighted Magnetic Resonance Imaging
  • Diffusion-Weighted MR Imaging
  • Diffusion-Weighted MRI
  • DWI
  • MR Diffusion-Weighted Imaging

Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Undergo DCE-MRI
Other Names:

Radiation: Fludeoxyglucose F-18
Undergo 18 FDG PET
Other Names:
  • 18FDG
  • FDG
  • fludeoxyglucose F 18
  • Fludeoxyglucose F18
  • Fluorine-18 2-Fluoro-2-deoxy-D-Glucose
  • Fluorodeoxyglucose F18

Radiation: Intensity-Modulated Radiation Therapy
Undergo IMRT
Other Names:
  • IMRT
  • Intensity Modulated RT
  • Intensity-Modulated Radiotherapy

Other: Laboratory Biomarker Analysis
Correlative studies

Procedure: Perfusion Magnetic Resonance Imaging
Undergo PWI
Other Name: magnetic resonance perfusion imaging

Procedure: Positron Emission Tomography
Undergo 18 F FDG-PET
Other Names:
  • Medical Imaging, Positron Emission Tomography
  • PET
  • Positron Emission Tomography Scan
  • Positron-Emission Tomography
  • proton magnetic resonance spectroscopic imaging

Drug: Temozolomide
Given PO
Other Names:
  • CCRG-81045
  • Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-
  • M & B 39831
  • M and B 39831
  • Methazolastone
  • RP-46161
  • SCH 52365
  • Temcad
  • Temodal
  • Temodar
  • Temomedac

Primary Outcome Measures :
  1. Progression-free survival (Phase II) [ Time Frame: At day 218 ]
    The fraction of patients alive and free of disease progression after the MRI scan scheduled. This fraction will be compared, using a one sample, two-sided exact binomial test, to 50% progression-free survival (PFS). For safety assessment, the study will be powered to ensure at least 85% chance of observing a serious adverse event, if the probability of such an event on treatment were >=5%.

  2. Safety profile and optimal dose of cediranib during chemoradiotherapy (Phase I) [ Time Frame: Up to 30 days after the last dose ]
    A dose-limiting toxicity of cediranib is defined as a clinically significant adverse event or abnormal laboratory value assessed as unrelated to disease progression, intercurrent illness, or concomitant medications/temozolomide and occurs following the first dose of cediranib in the chemoradiation.

Secondary Outcome Measures :
  1. Blood biomarkers (Phase II) [ Time Frame: Up to 1 year ]
    Log-transformation is expected to yield approximately homogenous and symmetric standard errors, both for Poisson events and quantities obtained by assays with successive dilutions. We will plot the median levels and quartiles over time. First, we will compare on-study values to baseline, than we will test for an association between treatment time and markers, using a linear mixed effects model with log-transformed data and a spline function of time. The two-sided, paired t-test test will be powered to detect an effect-size of 0.5.

  2. MRI parameters (Phase II) [ Time Frame: Up to 48 weeks ]
    The comparisons of all MRI measurements will be against their day -1 values (baseline), using a 2-sided, paired Wilcoxon test (Hollander and Wolfe 1973).

  3. Tumor biomarkers (Phase II) [ Time Frame: At baseline ]
    Exploratory analyses will be performed to determine if there is any correlation between the molecular/vascular phenotype of the tumor or quantitative measurements, we will use for this purpose ANOVA on log-transformed marker measurements. We will analyze changes in the measurements, and correlate biomarkers with clinical and radiographic response, similarly as for blood and urine biomarkers.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed glioblastoma

    • Newly diagnosed disease
  • Scheduled to receive standard post-surgical (i.e., biopsy or resection) temozolomide and radiotherapy
  • Must have residual, contrast-enhancing tumor (≥ 1 centimeter in ≥ 1 dimension)
  • Patients must be maintained on a stable corticosteroid regimen for 5 days prior to their baseline scan and for 5 days prior to their first vascular MRI; the dose of steroids should remain the same during the baseline vascular MRIs
  • Archival tumor tissue available for molecular analysis
  • No intratumoral hemorrhage or peritumoral hemorrhage by MRI
  • Karnofsky performance status 60-100%
  • Leukocytes ≥ 3,000/mcl
  • Absolute neutrophil count ≥ 1,500/mcL
  • Platelet count ≥ 100,000/mcL
  • Hemoglobin ≥ 8 g/dL
  • Total bilirubin normal
  • AST/ALT ≤ 2.5 times upper limit of normal
  • Creatinine normal OR creatinine clearance ≥ 60 mL/min
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Proteinuria ≤ 1+ on two consecutive dipsticks ≥ 7 days apart
  • Mini-mental status examination score ≥ 15
  • Must be able to tolerate MRI and must consent to participate in additional Vascular Imaging Procedures per protocol

    • CT scans cannot be substituted for MRI
  • Mean QTc ≤ 500 msec (with Bazett's correction) by electrocardiogram
  • No concurrent malignancy except curatively treated basal cell or squamous cell carcinoma skin cancer or carcinoma in situ of the cervix or breast

    • Patients with prior malignancies must be disease-free for ≥ 5 years
  • No history of familial long QT syndrome or other significant ECG abnormality
  • No history of allergic reactions attributed to compounds of similar chemical or biologic composition to cediranib
  • No uncontrolled intercurrent illness including, but not limited to, any of the following:

    • Hypertension (e.g., blood pressure > 140/90 mm Hg)
    • Ongoing or active infection
    • Symptomatic congestive heart failure
    • Unstable angina pectoris
    • Cardiac arrhythmia
    • Psychiatric illness/social situations that would preclude study compliance
  • No known coagulopathy that increases risk of bleeding
  • No history of clinically significant hemorrhages in the past
  • No New York Heart Association class III-IV heart disease
  • No condition requiring concurrent drugs or biologics with proarrhythmic potential
  • No other concurrent chemotherapy agents, investigational agents, or biologic therapy
  • No prior chemotherapy, radiotherapy, or any experimental therapy for this disease
  • No prior IV bevacizumab for any other medical condition
  • No prior carmustine implant (Gliadel Wafer)
  • No prior brachytherapy or radiosurgery for this disease
  • More than 30 days since prior and no other concurrent investigational agents or participation in an investigational therapeutic trial
  • At least 2 weeks since prior and no concurrent enzyme-inducing anti-epileptic drugs (EIAEDs)

    • Concurrent non-EIAEDs allowed
  • No concurrent CYP450-inducing anticonvulsants
  • No concurrent anticoagulants (e.g., dalteparin, warfarin, or low-molecular weight heparin)

    • If patients require warfarin or other anticoagulants (e.g., low-molecular weight heparin) while on study, then patient may continue treatment
  • No concurrent combination antiretroviral therapy for HIV-positive patients
  • No concurrent VEGF inhibitors
  • No concurrent pentamidine
  • No concurrent herbal or nontraditional medications

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00662506

Layout table for location information
United States, Massachusetts
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States, 02114
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Sponsors and Collaborators
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Tracy Batchelor Massachusetts General Hospital
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: National Cancer Institute (NCI) Identifier: NCT00662506    
Other Study ID Numbers: NCI-2009-00267
NCI-2009-00267 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
R01CA129371 ( U.S. NIH Grant/Contract )
PHS 398/2590
PHS 398/2590 ( Other Identifier: Massachusetts General Hospital Cancer Center )
8030 ( Other Identifier: CTEP )
P30CA006516 ( U.S. NIH Grant/Contract )
First Posted: April 21, 2008    Key Record Dates
Last Update Posted: September 21, 2017
Last Verified: September 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Maleic acid
Fluorodeoxyglucose F18
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors
Protein Kinase Inhibitors
Antiviral Agents
Anti-Infective Agents